The effectiveness of a standard 12-core prostate biopsy largely depends on the experience of the doctor. The most promising, non - invasive methods of additional imaging in prostate biopsy is histoscan. Using the latest software "True Targeting" allows you to perform a targeted biopsy in real time. This study is to evaluate the effectiveness of performing prostate biopsy under the control of histoscan in the one-day stay unit.

From May 2021 to December 2024. In the one-day stay unit on the basis of 10 multidisciplinary clinics 3650 patients with suspected prostate cancer underwent transrectal histoscan-guided prostate biopsy with "True Targeting" software.

The average prostate-specific antigen value was 13.23 ng/ml (range: 0.5 to 1900 ng/ml). The average age of the patients was 66 years old, and the average prostate volume was 54.89 cm3. There were 2997 patients (82%) having his first biopsy, and the other 658 patients (18%) having previous negative biopsy with non histoscan-guided biopsy. The presence of prostate cancer in close relatives was noted in 146 patients (4%). Among them, prostate cancer was detected in 126 patients, which is 86%. Suspicious sites were mainly located in the anterior sections of the prostate, which are usually missed when performing a standard transrectal biopsy. The overall incidence of prostate cancer was 64%, and with a standard biopsy this figure was 19%, while with a histoscan-targeted biopsy prostate cancer was diagnosed in 8% of cases. The average time of a transrectal histoscan-guided prostate biopsy is 16 minutes.

The conducted study showed high efficiency of prostate biopsy under histoscan-guided fashion in conditions of day stay unit. The use of this method allows to increase the detection of clinically significant prostate cancer and is valuable to further treatment tactics.